H1B Salary Data

Home › Employers › EyeBiotech, Inc.

EyeBiotech, Inc.: H-1B salaries and sponsorship

EyeBiotech, Inc. filed 4 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 2. Median offered salary: $125,000.

Applications (LCAs)4
Certified2
Employer addressRahway, NJ
H-1B dependent employerNo
Median offered salary$125,000
Middle half of salaries$125,000–$125,000
10th–90th percentile$125,000–$125,000

Does EyeBiotech, Inc. sponsor H-1B visas?

EyeBiotech, Inc. filed 4 labor condition applications in fiscal years 2023–2026, the latest submitted on Jan 2, 2025. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.

Salaries by job title

Job titleLCAsMedian salary
Clinical Research Associate (CRA) II4$125,000

Applications by fiscal year

Fiscal yearLCAsMedian salary
FY20254$125,000

Prevailing wage levels

The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.

Where the jobs are

Occupations

Latest applications

Job titleBase salaryLocationSubmittedStart dateStatus
Clinical Research Associate (CRA) II$125,000
Level II
Apex, NCJan 2, 2025Jan 3, 2025Certified
Clinical Research Associate (CRA) II$125,000
Level II
Rahway, NJJan 2, 2025Jan 3, 2025Certified
Clinical Research Associate (CRA) II$125,000
Level II
Apex, NCDec 26, 2024Jan 3, 2025Denied
Clinical Research Associate (CRA) II$125,000
Level II
Rahway, NJDec 26, 2024Jan 3, 2025Denied

Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).